Welcome to our dedicated page for EXACT SCIENCES SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exact Sciences Corp. filings document the regulatory record of a cancer diagnostics company whose public-company disclosures included material events, shareholder voting matters, capital structure, clinical and regulatory updates, operating results, and governance matters. The company’s securities disclosures identify common stock, convertible senior notes, and shelf-registered securities categories.
Recent filings also document corporate-status changes for EXAS, including Nasdaq removal from listing and registration for the common stock and a Form 15 certification covering termination or suspension of Exchange Act reporting duties. Related material-event reports and proxy materials describe transaction agreements, stockholder voting, litigation-related disclosures, and risk factors tied to the company’s public reporting transition.